Atezolizumab‐induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation

Atezolizumab is an immune checkpoint inhibitor (ICI) that is often associated with the development of several immune‐related adverse events, including fulminant type 1 diabetes mellitus (F1DM). Here, we present the case of a 73‐year‐old woman who was diagnosed with lung adenocarcinoma after surgical...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishioki, Toshihiko, Kato, Motoyasu, Kataoka, Shunichi, Miura, Keita, Nagaoka, Tetsutaro, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666772/
https://www.ncbi.nlm.nih.gov/pubmed/33224504
http://dx.doi.org/10.1002/rcr2.685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666772/
https://www.ncbi.nlm.nih.gov/pubmed/33224504
http://dx.doi.org/10.1002/rcr2.685

Ejemplares similares